Moderna says Omicron-specific booster generates strong immune response
2022.06.08 14:35
FILE PHOTO: A vial and a syringe are seen in front of a displayed Moderna logo, in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration
(Reuters) -Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine.
The booster raised virus-neutralizing antibodies by eight-fold in a study. The vaccine was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 micrograms level.
“We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer,” Chief Executive Stephane Bancel said in a statement.
Share of Moderna (NASDAQ:MRNA) were up 2% in premarket trading.
